Jim Cramer on Bristol-Myers: “I’m Backing off on It”

Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer offered insights on. Answering a caller’s query about the stock, Cramer stated:

“I’m backing off on it because I gotta tell you, I’m trying to see some good news in this Cobenfy that I was really all in on and I’m not getting that news yet. And the stock is telling me I’m wrong. I don’t like a stock telling me I’m wrong and not listening because you know what? Even though I got a problem with hearing, I can hear the footsteps of the people leaving Bristol-Myers. So that’s what I feel about it. It is in the Charitable Trust big meeting on Thursday. We’ll have to suss it out a little.”

Source: Unsplash

Bristol-Myers Squibb Company (NYSE:BMY) develops and markets biopharmaceutical products across oncology, hematology, immunology, cardiovascular, and neuroscience. During the November 5 episode, Cramer mentioned the company and said:

“Look, I, my Charitable Trust owns Bristol, looks like a mistake because I, I believed in Cobenfy, which is a, a pretty good product, but it’s not selling well at all.”

While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.